Orban J-C, Ichai C
Service de réanimation médicochirurgicale, hôpital Saint-Roch, 5, rue Pierre-Dévoluy, 06006 Nice cedex 01, France.
Ann Fr Anesth Reanim. 2007 May;26(5):440-4. doi: 10.1016/j.annfar.2007.03.001. Epub 2007 Apr 16.
The objective of the treatment of intracranial hypertension is to decrease intracranial pressure (ICP) while maintaining cerebral blood flow (CBF). Despite numerous treatments, none of them associates total efficiency and security. Systemic secondary cerebral injuries, which are responsible for cerebral ischemia, lead us to administer non specific treatments in order to optimize CBF and cerebral oxygenation. Thus, the goals are: 1) to maintain cerebral perfusion pressure> or =70 mmHg; 2) to control metabolic status by preventing hyperglycaemia, anaemia and hyperthermia; 3) to maintain normoxia and normocapnia (hypercapnia increases ICP and hypocapnia decreases CBF). Beside the neurosurgical evacuation of extra- and intraparenchymatous haematomas, osmotherapy and cerebrospinal fluid (CSF) evacuation are the two specific treatments of intracranial hypertension. Osmotherapy consists in an administration of a hypertonic solution which induces a decrease in cerebral water and finally in ICP. Mannitol (20%), which is the reference, associates osmotic and rheologic effects, and decreases CSF production too. Recent data conduct us to administer larger doses, between 0.7 and 1 g/kg in 15 minutes. Hypertonic saline solution associates osmotic effects and plasma volume loading. Thus, this solution is particularly appropriate in severe head injury with arterial hypotension. CBF evacuation decreases rapidly ICP without any major side-effect. Until now, there is no proof of a superior efficiency of a treatment for intracranial hypertension compared to another. Considering their mechanism of action, all of them are efficient but potentially dangerous too. Indeed, the choice between treatments depends on data which are issued from the multimodal monitoring. General non specific treatments are always necessary. Specific treatments are indicated if ICP is above 20-25 mmHg. Maintaining cerebral perfusion pressure represents the first therapeutic goal. If intracranial hypertension persists, evacuation of CBF or osmotherapy may be advocated. In case of refractory intracranial hypertension, it may be useful to deepen neurosedation. Controlled hypocapnia and barbiturates remain a third line therapy providing to monitor and maintain an appropriate CBF and cerebral oxygenation. Controlled hypothermia and decompressive craniectomy must be individually discussed.
颅内高压治疗的目标是在维持脑血流量(CBF)的同时降低颅内压(ICP)。尽管有多种治疗方法,但没有一种能同时具备完全的有效性和安全性。导致脑缺血的全身性继发性脑损伤,使我们采用非特异性治疗方法来优化CBF和脑氧合。因此,目标如下:1)维持脑灌注压≥70 mmHg;2)通过预防高血糖、贫血和体温过高来控制代谢状态;3)维持正常氧合和正常碳酸血症(高碳酸血症会增加ICP,低碳酸血症会降低CBF)。除了通过神经外科手术清除脑实质外和脑实质内血肿外,渗透性疗法和脑脊液(CSF)引流是颅内高压的两种特异性治疗方法。渗透性疗法是通过给予高渗溶液来降低脑含水量,最终降低ICP。作为参考药物的甘露醇(20%)兼具渗透和流变学效应,还能减少CSF生成。近期数据表明应给予更大剂量,即在15分钟内给予0.7至1 g/kg。高渗盐溶液具有渗透作用并能增加血浆容量。因此,该溶液特别适用于伴有动脉低血压的严重颅脑损伤。CSF引流可迅速降低ICP且无任何重大副作用。到目前为止,尚无证据表明一种颅内高压治疗方法比另一种具有更高的疗效。考虑到它们的作用机制,所有治疗方法都有效但也都有潜在危险。实际上,治疗方法的选择取决于多模式监测得出的数据。一般的非特异性治疗总是必要的。如果ICP高于20 - 25 mmHg,则需采用特异性治疗。维持脑灌注压是首要治疗目标。如果颅内高压持续存在,可考虑进行CSF引流或渗透性疗法。对于难治性颅内高压,加深神经镇静可能有用。控制性低碳酸血症和巴比妥类药物仍是三线治疗方法,需监测并维持适当的CBF和脑氧合。控制性低温和减压性颅骨切除术必须单独讨论。